ADR Biomedical Holdings Inc.
Notice of New Orders for High-Concentration Exosome Component Solution “NeoCella” Related Products
ADR Therapeutics, a consolidated subsidiary, secured a new order for NeoCella-related products. Total orders amount to 11,000 sets, with delivery scheduled for 2026-11-16. Sales are expected to correspond to 20% of the prior fiscal year’s net sales and will be recorded in Q3 of the fiscal year ending March 2027. The impact is currently under review.
Key Figures
- 11,000 sets
- 20% (equivalent to prior fiscal year net sales)
- 2026-11-16
AI要約
Business Developments
ADR Therapeutics (a consolidated subsidiary) is advancing R&D and sales structures for the high-concentration exosome component solution "NeoCella" and has received a contract to supply 11,000 sets to a general incorporated association as a new provision project. Delivery is scheduled for 2026-11-16, and the revenue scale is expected to be equivalent to 20% of the immediately preceding fiscal year’s net sales. Revenue will be recognized upon completion of product delivery and is expected to be recorded in Q3 of the fiscal year ending March 2027.
Financial Impact
The impact of this order on consolidated results is currently under review, and any matters that should be disclosed will be announced promptly. Although the order size may be material relative to annual net sales, specific figures and segmental impacts remain unknown.
ADR Biomedical Holdings Inc.
Company overview · Stock price · Financial data · All IR